By: Ashling Wahner From: onclive.com Patients with HER2-positive advanced or metastatic breast cancer who achieved a complete response (CR) or deep partial response (PR) to first-line trastuzumab deruxtecan (T-DXd; Enhertu) plus pertuzumab (Perjeta) experienced improved long-term outcomes, including more durable progression-free survival (PFS) outcomes and longer treatment durations, compared with those who experienced responses that were less deep, according to …
Updates In HER2-Low Breast Cancer Treatment Strategies
HER2-low breast cancer has changed one of the most familiar classifications in breast oncology. For many years, tumors that were not HER2-positive were generally managed as HER2-negative disease, with treatment decisions driven by hormone receptor status, prior therapy, disease tempo, and chemotherapy sensitivity. The development of trastuzumab deruxtecan has changed this framework by making low HER2 expression clinically actionable in …
HER2-Positive Breast Cancer Diet
From: healthline.com Your daily diet can affect your overall health. About 18% of all cancersTrusted Source may be related to diet, physical activity, and similar modifiable risk factors. Some foods may slow the growth of HER2-positive breast cancer by reducing the amount of HER2 protein the cancer cells make. Other foods may block cancer cells from getting nutrition or make …
A New First-line Option for Metastatic Breast Cancer
From: aacr.org Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for patients with newly diagnosed human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has either metastasized or cannot be removed with surgery. Concurrently, two tests …
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
By: Sabrina Serani From: targetedonc.com Key Takeaways CD47 expression levels may predict evorpacept efficacy in HER2-positive metastatic breast cancer, especially in heavily pretreated patients. Evorpacept combined with zanidatamab shows promising results, with a 56% objective response rate and 7.4 months median progression-free survival. The CD47-SIRPα pathway blockade by evorpacept enhances macrophage-mediated phagocytosis, potentially amplifying HER2-targeted therapy effects. Future research will …
Palbociclib improves progression-free survival in HER2 positive breast cancer
Source: PrECOG, LLC From: news-medical.net PrECOG, LLC, today announced the publication of final results from the pivotal phase 3 PATINA study in the New England Journal of Medicine (NEJM). The study evaluated whether adding palbociclib to anti-HER2 and endocrine therapy, following induction chemotherapy, could delay disease progression in patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–positive (HER2+) metastatic …
Tucatinib Enhances First-Line Maintenance Outcomes in HER2-Positive Metastatic Breast Cancer
By: Alexandra Gerlach, Editor From: pharmacytimes.com Key Takeaways Tucatinib added to trastuzumab and pertuzumab improved PFS by 8.6 months in patients with HER2+ metastatic breast cancer. The HER2CLIMB-05 trial showed consistent PFS benefits across subgroups, including those with brain metastases. Common adverse events with tucatinib included diarrhea and elevated liver enzymes, with manageable severity. Tucatinib integration into first-line maintenance therapy …
Evolving Strategies in the Management of HR+, HER2– Metastatic Breast Cancer
By: Guilherme Nader-Marta, MD, Erica L. Mayer, MD, MPH From: onclive.com Key Takeaways Sacituzumab govitecan improved PFS in untreated advanced TNBC patients not eligible for PD-(L)1 inhibitors, as shown in the ASCENT-03 trial. The ASCENT-04 trial demonstrated enhanced PFS with sacituzumab govitecan plus pembrolizumab in PD-L1–positive TNBC compared to chemotherapy plus pembrolizumab. Safety analysis indicated a favorable benefit/risk profile for …
Exciting Advances and Surprises: SABCS Highlights in HER2-Positive Advanced Breast Cancer
By;Patrice Wendling From: oncologynewscentral.com Data from key trials in HER2-positive advanced breast cancer were recently presented at the 2025 San Antonio Breast Cancer Symposium. Hope S. Rugo, MD, division chief of breast medical oncology and professor of medical oncology and therapeutics research at City of Hope Comprehensive Cancer Center in Duarte, California, shared her insights into how various findings may …
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
By: Paige Britt From: targetedonc.com Key Takeaways The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or death risk by 44% compared to the standard regimen. Median progression-free survival was 40.7 months, with an overall response rate of 85.1% for T-DXd plus pertuzumab. The safety profile of …